Adaptive Biotechnologies Corp (OQ:ADPT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1165 Eastlake Ave E
SEATTLE WA 98109
Tel: 1-650-8251656
Website: https://www.adaptivebiotech.com
IR: See website
<
Key People
Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Julie Rubinstein
President, Chief Operating Officer
Harlan S. Robins
Co-Founder, Chief Scientific Officer
Tycho Peterson
Chief Financial Officer
Francis Lo
Chief People Officer
Stacy Taylor
Senior Vice President, General Counsel, Corporate Secretary
Sharon Benzeno
Chief Commercial Office - Immune Medicine
   
Business Overview
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient's immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Financial Overview
For the fiscal year ended 31 December 2023, Adaptive Biotechnologies Corp revenues decreased 8% to $170.3M. Net loss increased 13% to $225.3M. Revenues reflect Immune meidicine revenue segment decrease of 31% to $67.5M. Higher net loss reflects Interest Expense increase from $4.2M to $13.8M (expense), Personnel expenses increase of 9% to $74.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.40 to -$1.56.
Employees: 709 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $72.92M as of Dec 31, 2023
Annual revenue (TTM): $170.28M as of Dec 31, 2023
EBITDA (TTM): -$179.38M as of Dec 31, 2023
Net annual income (TTM): -$225.25M as of Dec 31, 2023
Free cash flow (TTM): -$167.02M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 145,092,271 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.